Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Roche’s Avastin Fails to Win NICE Ovarian Cancer Backing

Dec. 18 (Bloomberg) -- Roche Holding anti-tumor drug Avastin fails to win backing of U.K. health-cost regulator as treatment for advanced ovarian cancer in a draft decision released today.

* National Institute for Health and Clinical Excellence

recommends against using drug at dosage for which it’s

currently licensed, the agency says in e-mailed statement * Roche will continue to work with NICE to secure positive

recommendation for Avastin, spokeswoman Silvia Dobry says in


Story: NSN MF6PHR6JIJVI <GO> For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.